Cellula Therapeutics key facts
as of Oct 2026- Developer of next-generation CAR-T cell therapies designed to cure solid tumours, specifically targeting aggressive brain cancers.
- Cellula Therapeutics is valued at approximately $13.9M as of Oct 2026 (last reported valuation).
- It has raised $3.6M; the latest was Early Stage VC ($3.6M) in Jul 2025.
- Notable investors include Remora Biotech, University of Geneva.
- Status: Privately Held (backing).
Cellula Therapeutics's last reported valuation, Jul 2025. Nothing priced has surfaced since.
- ·Watch Cellula Therapeutics: the Monday email on marks, rounds and moves
Cellula Therapeutics funding rounds
No funding rounds for Cellula Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Cellula Therapeutics
2Cellula Therapeutics valuation
Cellula Therapeutics's last reported valuation was $13.9 million in Jul 2025. No priced round, secondary trade or fund mark has surfaced since.
Cellula Therapeutics investors
2 investors are on record for Cellula Therapeutics, including Remora Biotech and University of Geneva.
About Cellula Therapeutics
Developer of next-generation CAR-T cell therapies designed to cure solid tumours, specifically targeting aggressive brain cancers. The company offers armoured immune cell effectors that utilise breakthrough pathways, enabling clients to access transformative treatments for difficult-to-treat solid tumours.
- Sector
- Healthcare
- HQ
- Lausanne, Switzerland
- Founded
- 2023
- Employees
- 7
- Ownership
- Privately Held (backing)
Is this your company? Profiles are maintained at PrivateMarketView, the data platform behind this page — sign in with your work email to keep it current, or tell us what's wrong.